2-乙氧基-4-羟基-6-甲基嘧啶 | 55996-04-8

• 物质功能分类: 医药中间体 - 杂环化合物 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 2-乙氧基-4-羟基-6-甲基嘧啶
• 英文名称: 6-methyl-2-etoxy-4(3H)-pyrimidinone
• 英文别名: 2-ethoxy-6-methyl-3H-pyrimidin-4-one；2-Aethoxy-6-methyl-3H-pyrimidin-4-on；2-ethoxy-6-methylpyrimidin-4(3H)-one；2-Ethoxy-4-hydroxy-6-methylpyrimidine；2-ethoxy-4-methyl-1H-pyrimidin-6-one
• CAS: 55996-04-8
• 化学式: C₇H₁₀N₂O₂
• mdl: MFCD09258880
• 分子量: 154.169
• InChiKey: CIJKVRCNKUAYKK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.428
• 拓扑面积：
  50.7
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933599090

反应信息

• 作为反应物：
  描述：

  2-乙氧基-4-羟基-6-甲基嘧啶 、 2-氰基-4'-溴甲基联苯 在 potassium carbonate 作用下， 以 乙腈 为溶剂， 反应 12.0h， 以56%的产率得到4'-[(2-ethoxy-4-methyl-6-oxopyrimidin-1(6H)-yl)methyl]biphenyl-2-carbonitrile
  参考文献：
  名称：

  WO2008/62905

  摘要：

  公开号：
• 作为产物：
  描述：

  2,4-二氯-6-甲基嘧啶 在 溶剂黄146 作用下， 生成 2-乙氧基-4-羟基-6-甲基嘧啶
  参考文献：
  名称：

  Interaction of Chloromethyl Ether with Pyrimidines.¹ I

  摘要：

  DOI：

  10.1021/ja01850a039

文献信息

• 6-alkyl and 5,6-dialkyl-2-methoxy-4(3H)- pyrimidinones in the transformations of pyrimidines—2
  作者：M. Botta、M. Cavalieri、D. Ceci、F. De Angelis、G. Finizia、R. Nicoletti

  DOI：10.1016/0040-4020(84)85016-4

  日期：1984.1

  The synthesis of 6-alkyl and 5,6-dialkyl-2-methoxy-4(3H)-pyrimidinones 3 is described. Their versatility to be transformed into 6-alkyl and 5,6-dialkyluracils 4(a-h), 6-alkyl and 5,6-dialkyl-3-methyluracils 7(a,e,f) and 6-alkyl and 5,6-dialkyl-2-alkoxy-4(3H)-pyrimidinones 5(a-i) is also shown.

  描述了6-烷基和5，6-二烷基-2-甲氧基-4（3H）-嘧啶酮3的合成。它们的多功能性可转化为6烷基和5,6-二烷基尿嘧啶4（ah），6-烷基和5,6-二烷基-3-甲基尿嘧啶7（a，e，f）和6烷基和5,6-还显示了二烷基-2-烷氧基-4（3H）-嘧啶酮5（ai）。
• HETEROMONOCYCLIC COMPOUND AND USE THEREOF
  申请人：Kuroita Takanobu

  公开号：US20080207654A1

  公开（公告）日：2008-08-28

  A compound represented by the formula (I): wherein R1 is an oxo group, ═N—R or the like; a group represented by the formula: is a group represented by the formula: R2 is a group represented by the formula: R3 and R4 are each H, or C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkoxy, C1-C6 alkylamino, di(C1-C6)alkylamino or C1-C6 alkylthio, each of which is optionally substituted; and R5 is H, or C1-C6 alkyl, C2-C6 alkenyl, cyclic group, each of which is optionally substituted, —CO—R8 or —O—R8′, or a salt thereof. The compound of the present invention is useful as a drug for the prophylaxis or treatment of circulatory diseases, metabolic diseases and/or central nervous system diseases.

  化合物的化学式为(I)，其中R1为氧代基，═N—R或类似基团；式中的基团表示为：其中R2为式中的基团；R3和R4分别为H，或C1-C6烷基，C3-C6环烷基，C1-C6烷氧基，C1-C6烷基氨基，二(C1-C6)烷基氨基或C1-C6烷基硫基，每个基团均可选地被取代；R5为H，或C1-C6烷基，C2-C6烯基，环状基团，每个基团均可选地被取代，—CO—R8或—O—R8′，或其盐。本发明的化合物可用作预防或治疗循环系统疾病、代谢性疾病和/或中枢神经系统疾病的药物。
• Substituted pyrimidines and [1,2, 4] triazoles and the use thereof for treating prophylaxis, cardiovascular diseases, metabolic diseases and/or central nervous system diseases
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US07998968B2

  公开（公告）日：2011-08-16

  A compound represented by the formula (I): wherein R1 is an oxo group, ═N—R or the like; a group represented by the formula: is a group represented by the formula: R2 is a group represented by the formula: R3 and R4 are each H, or C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkoxy, C1-C6 alkylamino, di(C1-C6)alkylamino or C1-C6 alkylthio, each of which is optionally substituted; and R5 is H, or C1-C6 alkyl, C2-C6 alkenyl, cyclic group, each of which is optionally substituted, —CO—R8 or —O—R8′, or a salt thereof. For example, the compound may be substituted pyrimidines and pharmaceutical compositions of the formula (I) where X=—CR3; X1=—CR2 or —NR2; and X2=—CR5 or —NR5. The compound of the present invention is useful as a drug for the prophylaxis or treatment of cardiovascular diseases, metabolic diseases and/or central nervous system diseases.

  化合物的化学式为(I)：其中R1是氧代基，═N—R或类似的基团；由式子表示的基团：是由式子表示的基团：R2是由式子表示的基团：R3和R4分别是H，或C1-C6烷基，C3-C6环烷基，C1-C6烷氧基，C1-C6烷基氨基，二(C1-C6)烷基氨基或C1-C6烷基硫基，每个基团都可以选择性地被取代；而R5是H，或C1-C6烷基，C2-C6烯基，环状基团，每个基团都可以选择性地被取代，—CO—R8或—O—R8′，或其盐。例如，该化合物可以是取代的嘧啶，并且具有化学式(I)的制药组合物，其中X=—CR3；X1=—CR2或—NR2；X2=—CR5或—NR5。本发明的化合物可用作预防或治疗心血管疾病、代谢性疾病和/或中枢神经系统疾病的药物。
• Heteromonocyclic compound or a salt thereof having strong antihypertensive action, insulin sensitizing activity and the like production thereof and use thereof for prophylaxis or treatment of cardiovascular diseases, metabolic diseases and/or central nervous system diseases
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US07803940B2

  公开（公告）日：2010-09-28

  A compound represented by the formula (I): wherein R1 is an oxo group, ═N—R or the like; a group represented by the formula: is a group represented by the formula: R2 is a group represented by the formula: R3 and R4 are each H, or C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkoxy, C1-C6 alkylamino, di(C1-C6)alkylamino or C1-C6 alkylthio, each of which is optionally substituted; and R5 is H, or C1-C6 alkyl, C2-C6 alkenyl, cyclic group, each of which is optionally substituted, —CO—R8 or —O—R8′, or a salt thereof. The compound of the present invention is useful as a drug for the prophylaxis or treatment of cardiovascular diseases, metabolic diseases and/or central nervous system diseases.

  化合物的化学式为(I)，其中R1代表氧代基，═N—R或类似基团；式中代表的基团为：R2代表式中代表的基团；R3和R4分别代表氢、C1-C6烷基、C3-C6环烷基、C1-C6烷氧基、C1-C6烷基氨基、双(C1-C6)烷基氨基或C1-C6烷基硫基，每个基团都可以选择性地被取代；R5代表氢、C1-C6烷基、C2-C6烯基、环状基团，每个基团都可以选择性地被取代，—CO—R8或—O—R8′，或其盐。本发明的化合物可用作预防或治疗心血管疾病、代谢性疾病和/或中枢神经系统疾病的药物。
• Heteromonocyclic compound and use thereof
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP2256115A1

  公开（公告）日：2010-12-01

  A compound represented by the formula (I): wherein R1 is an oxo group, =N-R or the like; a group represented by the formula: is a group represented by the formula: R2 is a group represented by the formula: R3 and R4 are each H, or C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkoxy, C1-C6 alkylamino, di(C1-C6)alkylamino or C1-C6 alkylthio, each of which is optionally substituted; and R5 is H, or C1-C6 alkyl, C2-C6 alkenyl, cyclic group, each of which is optionally substituted, -CO-R8 or -O-R8', or a salt thereof. The compound of the present invention is useful as a drug for the prophylaxis or treatment of circulatory diseases, metabolic diseases and/or central nervous system diseases.

  式 (I) 所代表的化合物： 其中 R1 是氧代基团、=N-R 或类似基团；由式（I）代表的基团： 是由式(I)代表的基团 R2 是由式......表示的基团： R3和R4各自为H，或C1-C6烷基、C3-C6环烷基、C1-C6烷氧基、C1-C6烷基氨基、二(C1-C6)烷基氨基或C1-C6烷硫基，其中每个基团任选被取代；R5为H，或C1-C6烷基、C2-C6烯基、环状基团，其中每个基团任选被取代，-CO-R8或-O-R8'，或其盐。本发明的化合物可用作预防或治疗循环系统疾病、代谢疾病和/或中枢神经系统疾病的药物。